Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center
Clinical and Applied Thrombosis/Hemostasis · 2025
DOI: 10.1177/10760296251405425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2025. Verfasst von Alyssa R George und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA. Hauptthemen laut MEDLINE: Factor VIIa, Hemophilia A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Eptacog alfa and eptacog beta are recombinant factor VIIa (rFVIIa) agents approved for use in hemophilia A or B with inhibitors. Our institution converted from eptacog alfa to eptacog beta as the preferred rFVIIa product. The objective of this medication use evaluation was to review the utilization of both agents and cost savings associated with the conversion.
Methods
We performed a retrospective chart review for all eptacog alfa and beta administrations from October 2023 through September 2024. We evaluated product selection and dosing as well as the occurrence of thrombosis, new bleeding events, or existing bleeding that required therapy escalation. Cost savings were estimated using wholesale acquisition costs.
Results
There were 17 patients that required 27 admissions for rFVIIa (eptacog alfa: 3, 11.1% and eptacog beta: 21, 77.8%). Three administrations (11.1%) utilized both agents. Indications included bleeding in hemophilia patients (12, 44.4%), followed by peri-procedural management (9, 33.3%), cardiac surgery (3, 11.1%), and anticoagulation reversal for life-threatening bleeding (3, 11.1%). There were 21 administrations in which eptacog beta was exclusively used (bleeding in hemophilia A (9, 33.3%), peri-procedural management (7, 25.9%), cardiac surgery (2, 7.4%), and anticoagulation reversal (3, 11.1%)). There were no thrombotic events. There were 5 patients (18.5%) who required rFVIIa dose escalation and two (7.4%) who required re-initiation of rFVIIa. Cost avoidance was estimated at $554,400 over a 12-month period.
Conclusion
We treated a small cohort of patients with eptacog beta without adverse outcomes. Other hospitals might evaluate their rFVIIa use and consider opportunities for substitution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Henry Ford Hospital, Detroit, MI, USA.
- Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
- Center for Drug Policy, Mass General Brigham, Somerville, MA, USA.
- Vasculearn Network, Wakefield, MA, USA.
- Department of Hematology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Hematology, Brigham and Women's Hospital, Boston, MA, USA.
ORCID-Profile: Alyssa R George, Katelyn W Sylvester, Dareen M Kanaan, John R Fanikos, Jean M Connors, Nathan T Connell
Zitieren
APA
George, A. R., Sylvester, K. W., Kanaan, D. M., Reddy, P., Fanikos, J. R., Connors, J. M., & Connell, N. T. (2025). Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296251405425
Vancouver
George AR, Sylvester KW, Kanaan DM, Reddy P, Fanikos JR, Connors JM, et al. Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center. Clinical and Applied Thrombosis/Hemostasis. 2025. doi:10.1177/10760296251405425
BibTeX
@article{George2025,
author = {George, Alyssa R and Sylvester, Katelyn W and Kanaan, Dareen M and Reddy, Prabashni and Fanikos, John R and Connors, Jean M and Connell, Nathan T},
title = {Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2025},
doi = {10.1177/10760296251405425}
}
EUVIMED